Risk factors in coronary atherosclerosis athero-inflammations: The meeting point

Thrombosis Journal

Volumn 1, Issue , 2003, Pages

  Altman, Raul ^a  

^a UNIVERSIDAD NACIONAL DE TUCUMÁN   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ACUTE PHASE PROTEIN; ARGININE; ATORVASTATIN; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR; C REACTIVE PROTEIN; CD40 LIGAND; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GELATINASE B; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLUENZA VACCINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 18; INTERLEUKIN 6; LEPTIN; LIPID; LIPOPROTEIN A; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; SIMVASTATIN; TISSUE FACTOR PATHWAY INHIBITOR; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ARTERY THROMBOSIS; ATHEROMA; BACTERIAL INFECTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR INFLAMMATION; CARDIOVASCULAR RISK; CHLAMYDIASIS; CIGARETTE SMOKING; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG MECHANISM; GENETIC PREDISPOSITION; HUMAN; HYPERTENSION; IMMUNE RESPONSE; IMMUNITY; IMMUNOPATHOLOGY; INFLUENZA; NONHUMAN; OBESITY; PLEIOTROPY; PROTECTION; PROTEIN FUNCTION; RESTENOSIS; REVIEW; RISK FACTOR; THROMBOGENESIS; UNSTABLE ANGINA PECTORIS; VASCULAR ENDOTHELIUM; VIRUS INFECTION;

EID: 1542776567     PISSN: 14779560     EISSN: None     Source Type: Journal    
DOI: 10.1186/1477-9560-1-4     Document Type: Review

References (161)

1. Ross R: Atherosclerosis: an inflammatory disease N Engl J Med 1999, 340:115-126.
2. Vorchheimer DA and Fuster V: Inflammatory markers in coronary artery disease. Let prevention douse the flames JAMA 2001, 286:2154-2156.
3. Ross R: The pathogenesis of atherosclerosis-a perspective for the 1990s Nature 1993, 362:801-809.
4. Rosenzweig A: Endothelial Progenitor Cells N Eng J Med 2003, 348:581-582.
5. Cybulsky MI and Gimbrone MA Jr: Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis Science 1991, 251:788-791.
6. Bonetti PO, Lerman LO and Lerman A: Endothelial dysfunction. A marker of atherosclerotic risk Arterioscler Thromb Vasc Biol 2003, 23:168-175.
7. Sela S, Shurtz-Swirski R, Awad J, Shapiro G, Nasser L, Shasha SM and Kristal B: The involvement of peripheral polymorphonuclear leukocytes in the oxidative stress and inflammation among cigarette snokers Israel Med Ass J 2002, 4:1015-1019.
8. Levi M, de Jonge E, van der Poll T and ten Cate H: Disseminated intravascular coagulation Thromb haemost 1999, 82:695-705.
9. Moreno PR, Bernardi VH and Lopez-Cuellar J et al.: Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes Circulation 1996, 94:3090-3097.
10. Shebuski RJ and Kilgore KS: Role of inflammatory mediators in thrombogenesis J. Pharmacol Exp Ther 2002, 300:729-735.
11. Mann KG, Butenas S and Brummel K: The dynamics of thrombin formatiom Arterioscler Thromb Vasc Biol 2003, 23:17-25.
12. Matthay MA: Severe sepsis-A new treatment with both anticoagulant and antiinflamatory properties N Engl J Med 2001, 344:759-762.
13. Gimbrone MA Jr, Topper JN, Nagel T, Anderson KM and Garcia Cardeña G: Endothelial dysfunction, hemodynamic forces, and atherogenesis Ann NY Acad Sci 2000, 105:1567-1572.
14. Prentice CRM: Platelets and atherosclerosis Eur Heart J 1999, 1(supplA):A3-A7.
15. Altman R and Scazziota A: Role of anti-inflammatory drugs in the treatment of acute coronary syndromes. From atheroinflammation to athero-thrombosis Rev Esp Cardiol 2003, 56:9-15.
16. Altman R, Rouvier J and Scazziota A: Secondary prevention of myocardial infarction. Beneficial effect of combining oral anticoagulant plus aspirin: therapy based on evidence Clin Appl Thromb Hemost 2000, 6:126-134.
17. Farb A, Burke AP, Tang AL, Liang Y, Poonam Mannan MS, Smialek J and Virmani R: Coronary plaque erosion without rupture into a lipid core Circulation 1996, 93:1354-1363.
18. Mailhac A, Badimon JJ and Fallon JT et al.: Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis. Relative contribution of fibrin(ogen) and platelets Circulation 1994, 90:988-996.
19. Gimbrone MA Jr: Endothelial disfunction, hemodynamic forces, and atherosclerosis Thrombos haemost 1999, 82:722-726.
20. Henn V, Slupsky JR and Grafe M et al.: CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells Nature 1998, 391:591-594.
21. Sata M, Saiura A and kunusato A et al.: Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis Nat Med 2002, 8:403-409.
22. Hill JM, Zalos G and Halcox JPJ et al.: Circulating endothelial progenitor cells, vascular function, and cardiovascular risk N Engl J Med 2003, 348:593-600.
23. Duggirala R, Gonzalez Villalpando C, O'Leary DH, Stern MP and Blangero J: Genetic basis of variation in carotid artery wall thickness Stroke 1996, 27:833-837.
24. Jerrard-Dunne P, Markus HS, Steckel DA, Buehler A, von Kegler S and Sitzer M: Early carotid atherosclerosis and family history of vascular disease. Specific effects on arterial sites have implications for genetic studies Arteriosscler Thromb Vasc Biol 2003, 23:302-306.
25. Welt FGP and Rogers C: Inflammation and restenosis in the stent era Arterioscler Thromb Vasc Biol 2002, 22:1769-1776.
26. Moreno PR, Bernardi VH and Lopez-Cuellar J et al.: Macrophages infiltration predicts restenosis after coronary intervention in patients with unstable angina Circulation 1996, 94:3098-3102.
27. Altman R, Rouvier J, Scazziota A and Gonzalez C: No causal association between inflammation and Chlamydia Pneumoniae in patients with chronic ischemic arterial disease Inflammation 2002, 26:25-30.
28. Liuzzo G, Biasucci LM and Gallimore JL et al.: The pronostic value of C-reactive protein and serum amyloid A protein in severe unstable angina N Engl J Med 1994, 331:417-424.
29. Biasucci LM, Vitelli A and Liuzzo G et al.: Elevated level of interleukin-6 in ustable angina Circulation 1996, 94:874-877.
30. Blake GJ and Ridker PM: Novel clinical markers of vascular wall inflammation Circulation Res 2001, 89:763-771.
31. Libby P, Ridker PM and Maseri A: Inflammation and Atherosclerosis Circulation 2002, 105:1135-1143.
32. Wu KK, Aleksic N, Ballantyne Ch M, Ahn Ch, Juneja H and Boerwinkle E: Interaction between soluble thrombomodulin and Intercellular Adhesion Molecule-1 in predicting risk of coronary heart disease Circulation 2003, 107:1729-1732.
33. Blankenberg S, Tiret L and Bickel Ch et al.: Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina Circulation 2002, 106:24-30.
34. Kai H, Ikeda H and Yasukawa H et al.: Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes J Am Coll Cardiol 1998, 32:368-372.
35. Blankenberg S, Rupprecht HJ and Odette Poirier O et al.: Plasma Concentrations and Genetic Variation of Matrix Metalloproteinase 9 and Prognosis of Patients With Cardiovascular Disease Circulation 2003, 107:1579-1585.
36. Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention Circulation 2003, 107:363-369.
37. Pasceri V, Willerson JT and Yeh ET: Direct proinflammatory effect of C-reactive protein on human endothelial cells Circulation 2000, 102:2165-2168.
38. Devaraj S, Yan Xu D and Jialai I: C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells. Implications for the metabolic syndrome and atherothrombosis Circulation 2003, 107:398-404.
39. Ishikawa T, Hatakeyama K and Imamura T et al.: Involvement of Creactive protein obtained by directional coronary atherotomy in plaque instability and developing restenosis in patients with stable or unstable angina pectoris Am J Cardiol 2003, 91:287-292.
40. Bhatt DL and Topol EJ: Need to test the arterial inflammation hypothesis Circulation 2002, 106:136-140.
41. Ridker PM, Buring JE, Cook NR and Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. An 8-years follow-up of 14719 initially healthy american women Circulation 2003, 107:391-397.
42. Mosca L: C-reactive protein-To screen or not to screen N Engl J Med 2002, 347:1615-1617.
43. Kereiakes DJ: The fire that burns within. C-reactive protein Circulation 2003, 107:373-374.
44. Yeh ETH and Willerson JT: Coming of age of C-reactive protein. Using inflammation markers in cardiology Circulation 2003, 107:370-372.
45. Lloyd-Jones DM and Levy D: C-reactive protein in the prediction of cardiovascular events N Engl J Med 2003, 348:1059-1061.
46. Deedwania PC: Diabetes and vascular disease: Common links in the emerging epidemic of coronary artery disease Am J Cardiol 2003, 91:68-71.
47. Haffner SM, Lehto S, Ronnemaa T, Pyroala K and Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 1998, 339:229-234.
48. Mooradian AD: Cardiovascular disease in type 2 diabetes mellitus Arch Intern Med 2003, 163:33-40.
49. Guerci B, Böhme P, Kearney-Schawartz A, Zannad F and Drouin P: Endothelial dysfuction and type 2 diabetes Diabetes Metab 2001, 27:436-447.
50. Ouvina SM, La Greca RD, Zanaro NL, Palmer L and Sassetti B: Endothelial dysfunction, nitric oxide and platelet activation in hypertensive and diabetic type II patients Thromb Res 2001, 102:107-114.
51. Lakka HM, Laaksonen DE and Lakka TA et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men JAMA 2002, 288:2709-2716.
52. Neil A, Hawkins M, Potok M, Thorogood M, Cohen D and Mann JA: A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM Diabetes Care 1993, 16:1003-9936.
53. Marshall SM: Blood control pressure, microalbuminuria and cardiovascular risk in Type 2 diabetes mellitus Diabet Med 1999, 16:358-372.
54. Guerrero-Moreno F and Rodriguez-Moran M: Proteinuria is an independent risk factor for ischemic stroke in non-insulin-dependent diabetes mellitus Stroke 1999, 30:1787-1791.
55. Evans M, Khan N and Rees A: Diabetic dyslipidaemia and coronary heart disease: new perspectives Curr Opin Lipidol 1999, 10:387-391.
56. Pandolfi A, Cetrullo D and Polishuck R et al.: Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects Arterioscl Thromb Vasc Biol 2001, 21:1378-1382.
57. Tschoepe D, Roesen P and Kaufmann L et al.: Evidence for abnormal platelet glycoprotein expression in diabetes mellitus Eur J Clin Invest 1990, 20:166-170.
58. Davi G, Catalano I and Averna M et al.: Thromboxane biosynthesis and platelet function in type II diabetes mellitus N Engl J Med 1990, 322:1769-1774.
59. Paton RC and Passa P: Platelet and diabetic vascular disease Diabete Metab 1983, 4:306-312.
60. Knobler H, Savion N, Shenkman B, Kotev-Emeth S and Varon D: Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients Thromb Res 1998, 90:181-190.
61. Kessler L, Weisel ML, Attali P, Mossard JM, Cazenave JP and Pinget M: Von Willebrand factor in diabetic angiopathy Diabetes Metab 1998, 24:327-336.
62. Roffi M, Chew DP and Mukherjee D et al.: Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes Circulation 2001, 104:2767-2771.
63. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG and Topol EJ: Abciximab reduces mortality in diabetics following percutaneous coronary intervention J Am Coll Cardiol 2000, 15:922-928.
64. Eckel RH, Wassef M, Chait A, Sobel B, Barrett E, King E, Lopes-Virella M, Reusch J, Ruderman N, Steiner G and Vlassara H: Prevention Conference VI: Diabetes and Cardiovascular Disease Writing Group II: Pathogenesis of atherosclerosis in diabetes Circulation 2002, 105:138-143.
65. Ford ES: Body mass index, diabetes, and C-reactive protein among US adults Diabetes Care 1999, 22:1971-1977.
66. Thorand B, Löwel H and Schneider A et al.: C-reactive protein as a predictor for incident diabetes mellitus among middleaged men. Results from the MONICA Augsburg cohort study. 1984 - 1998 Arch Intern Med 2003, 163:93-99.
67. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K and Freed MI: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus Circulation 2002, 106:679-684.
68. Marx N, Froehlich J and Siam L et al.: Antidiabetic PPARγ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease Arterioscler Thromb Vasc Biol 2003, 23:283-288.
69. Libby P, Ridker PM and Maseri A: Inflammation and atherosclerosis Circulation 2002, 105:1135-1143.
70. Hanson RL, Imperatore G, Bennett PH and Knowler WC: Components of the "metabolic syndrome" and incidence of type 2 diabetes Diabetes 2002, 51:3120-3127.
71. Morishita E, Asakura H and Saito M et al.: Elevated plasma levels of free-form of TFPI antigen in hypercholesterolemic patients Atherosclerosis 2001, 154:203-212.
72. Dichtl W, Nilsson L and Goncalves I et al.: Very low-density lipoprotein activated nuclear factor-kB in endothelial cells Circ Res 1999, 84:1085-1094.
73. Ceriello A, Taboga C and Tonutti L et al.: Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation Effects of short- and long-term simvastatin treatment Circulation 2002, 106:1211-1218.
74. Ioka T, Tasaki H and Yashiro A et al.: Association between plasma lipoprotein(a) and endothelial dysfuction normocholesterolemic and non-diabetic subjects with angiographically normal coronary arteries Circ J 2002, 66:267-271.
75. Cominacini L, Fratta Pasini A and Garbin U et al.: The plateletendothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells J Am Coll Cardiol 2003, 41:499-507.
76. Blake GJ and Ridker PM: Are statins anti-inflammatory? Curr Control Trials Cardiovasc Med 2000, 1:161-165.
77. Simes RJ, Marschner IC and Hunt D et al.: Relationship Between Lipid Levels and Clinical Outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Trial. To What Extent Is the Reduction in Coronary Events With Pravastatin Explained by On-Study Lipid Levels? Circulation 2002, 105:1162-1169.
78. Yeung AC and Tsao P: Statin Therapy. Beyond Cholesterol Lowering and Antiinflammatory Effects Circulation 2002, 105:2937-2938.
79. Ridker PM, Rifai N and Lowenthal SP: Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia Circulation 2001, 103:1191-1193.
80. Eto M, Kozai T and Cosentino F et al.: Statin prevent tissue factor expression in human endothelial cells: role of the Rho/Rhokinase and Akt pathways Circulation 2002, 105:1756-1759.
81. Corti R, Farkouh ME and Badimon JJ: The vulnerable plaque and acute coronary syndromes Am J Med 2002, 113:668-680.
82. Blake GJ and Ridker PM: Novel clinical markers of vascular wall inflammation Circulation Res 2001, 89:763-771.
83. Dichtl W, Dulak J and Frick M et al.: HMG-CoA reductade inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells Arteroscler Tromb Vasc Biol 2003, 23:58-63.
84. Hernandez-Presa MA, Martin-Ventura JL and Ortego M et al.: Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells Atheroslerosis 2002, 160:49-58.
85. Llevadot J, Murasawa S and Kureishi Y et al.: HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells J Clin Invest 2001, 108:399-405.
86. Horsmans Y: Differential metabolism of statins: Importance in drug-drug interactions Eur Heart J Suppl 1999, 1(SupplT):T7-T12.
87. Wiklund O, Mattsson-Hulten L, Hurt-Camejo E and Oscarsson J: Effects of simvastatin and atorvastatin on inflammation markers in plasma J Intern Med 2002, 25:338-347.
88. Mukamal KJ, Conigrave KM and Mittleman MA et al.: Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men N Engl J Med 2003, 348:163-164.
89. Albert MA, Glynn RJ and Ridker PM: Alcohol consumption and plasma concentration of C-reactive protein Circulation 2003, 107:443-447.
90. Hubert HB, Fenileib M and McNamara PM et al.: Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham heart study Circulation 1983, 67:968-977.
91. Kim KS, Owen WL and Williams D et al.: A comparison between BMI and conicity index on predicting coronary heart disease: the Framingham Heart Study Ann Epidemiol 2000, 10:424-431.
92. Cooke JP and Oka RK: Does leptin cause vascular disease Circulation 2002, 106:1904-1905.
93. Eckel RH and Krauss RM: American Heart Association call to action: obesity as a major risk factor for coronary heart disease: AHA Nutrition Committee Circulation 1998, 97:2099-2100.
94. Rimm EB, Stampfer MJ and Giovannucci E et al.: Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men Am J Epidemiol 1995, 141:1117-1127.
95. Visser M, Bouter LM and McQuillan GM et al.: Elevated C-reactive protein levels in overweight and obese adult JAMA 1999, 282:2131-2135.
96. Tchernof A, Nolan A and Sites CK et al.: Weight loss reduces Creative protein levels in obese postmenstrual women Circulation 2002, 105:564-569.
97. Esposito K, Pontillo A and Di Palo C et al.: Effect of Weight Loss and Lifestyle Changes on Vascular Inflammatory Markers in Obese Women A Randomized Trial JAMA 2003, 289:1799-1804.
98. Grundy SM: Obesity, metabolic syndrome, and coronary atherosclerosis Circulation 2002, 105:2696-2698.
99. Festa A, D'Agostino R Jr and Williams K et al.: The relation of body fat mass and distribution to markers of chronic inflammation Int J Obes Relat Metab Disord 2001, 25:1407-1415.
100. Fridman JM and Halaas JL: Leptin and the regulation of bodyweight in normals Nature 1998, 395:763-770.
101. Singhal A, Farooqi S and Cole TJ et al.: Influence of leptin on arterial distensibility a novel link between obesity and cardiovascular disease? Circulation 2002, 106:1919-1924.
102. Binder Ch J, Chang MK and Shaw PX et al.: Innate and acquired immunity in atherogenesis Nature Med 2002, 8:1218-1226.
103. Hanson GK, Libby P, Schönberck U and Yan Z: Innate and adaptive immunity in the pathogenesis of atherosclerosis Circ Res 2002, 91:281-291.
104. Edfeldt K, Swedenborg J and Hansson GK et al.: Expression of tolllike receptors in human atherosclerotic lesions A possible pathway for plaque activation Circulation 2002, 105:1158-1161.
105. Sasu S, LaVerda D and Qureshi N et al.: Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen activated protein kinase activation Circ Res 2001, 89:244-250.
106. Kiechl S, Lorenz E and Reindl M et al.: Toll-like receptor 4 polymorphisms and atherogenesis N Engl J Med 2002, 347:185-92.
107. Woodhouse PR, Khaw KT, Plummer M, Foley A and Meade TW: Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease Lancet 1994, 343:435-439.
108. Tillett HE, Smith JWG and Gooch CD: Excess death attributable to influenza in England and Wales: Age and death and certified cause Int J Epidemiol 1983, 12:344-352.
109. Van Lenten BJ, Wagner AC and Anantharamaiah GM et al.: Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide Circulation 2002, 106:1127-1132.
110. Naghavi M, Barlas Z and Siadaty S et al.: Association of influenza vaccination and reduced risk of recurrent myocardial infarction Circulation 2000, 102:3039-3045.
111. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K and Iwane : Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly N Eng J Med 2003, 348:1322-1332.
112. Gurfinkel EP, de la Fuente RL, Mendiz O, Mautner B and FESC for the FLUVACS Study Group: Influenza Vaccine Pilot Study in Acute Coronary Syndromes and Planned Percutaneous Coronary Interventions The FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study Circulation 2002, 105:2143-2147.
113. Galve-de Rochemonteix B, Kobayashi T and Rosnoblet C et al.: Interaction of anti-phospholipid antibodies with late endosomes of human endothelial cells Arterioscler Thromb Vasc Biol 2000, 20:563-574.
114. Del Papa N, Guidali L and Spatola L et al.: Relationship between anti-phospholipid and anti-endothelial cell antibodies III: beta 2 glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules Clin Exp Rheumatol 1995, 13:179-185.
115. Rand JH: Molecular pathogenesis of the antiphospholipid syndrome Circulation Research 2002, 90:29-37.
116. Pierangeli SS, Espinola RG, Liu X and Harris EN: Thrombogenic effects of antiphospholipid antibodies are mediated by Intercellular Cell Adhesion Molecule-1, Vascular Cell Adhesion Molecule-1, and P-Selectin Circ Res 2001, 88:245-250.
117. Libby P, Egan D and Skarlatos S: Roles of infectious agents in atherosclerosis and restenosis Circulation 1997, 96:4095-4103.
118. Danesh J, Collins R and Peto R: Chronic infections and coronary heart disease: is there a link? Lancet 1997, 350:430-436.
119. Metha JL, Saldeen TGP and Rand K: Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease J Am Coll Cardiol 1998, 31:1217-1225.
120. Gurfinkel E, Bozovich G and Darroca A et al.: For the ROXIS Study group. Randomized trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study Lancet 1997, 350:404-407.
121. Muhlestein JB, Anderson JL and Carlquist JF et al.: Randomized secondary prevention trial of azithromycin in patients with coronary artery disease. Primary clinical results of the ACADEMIC study Circulation 2000, 102:1755-1760.
122. Sinisalo J, Mattila K and Valtonen V et al.: Effect of 3 months of antimicrobial treatment with clarithromicin in acute non-Qwave coronary syndrome Circulation 2002, 105:1555-1560.
123. Stone AFM, Mendall MA and Kaski JC et al.: Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of Inflammation and cardiac events in patients with acute coronary syndromes South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA) Circulation 2002, 106:1219-1223.
124. Smieja M, Gnarpe J and Lonn E et al.: Multiple infection and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) study Circulation 2003, 107:251-257.
125. Cercek B, Shah PK and Noc M et al.: Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial Lancet 2003, 361:809-813.
126. Nieminen MS, Mattila K and Valtonen V: Infection and inflammation as risk factors for myocardial infarction Eur Heart J 1993, 14(Supp K):12-16.
127. Ericson K, Saldeen GP, Lindquist O, Pahlson C and Mehta JL: Relationship of Chlamydia pneumoniae infection to severity of human coronary atherosclerosis Circulation 2000, 101:2568-2571.
128. Gharavi EE, Chaimovich H and Cucurull E et al.: Induction of antiphospholipid antibodies by immunization with synthetic viral and bacterial peptides Lupus 1999, 8:449-455.
129. Kuo CC, Jackson LA, Lee A and Grayston JT: In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae Antimicrob agents chemother 1996, 40:2667-2669.
130. Martin D, Bursill J, Qui MR, Breit SN and Campbell T: Alternative hypothesis for efficacy of macrolides in acute coronary syndromes Lancet 1998, 351:1858-1859.
131. Agen C, Danesi R and Blandizzi C et al.: Macrolide antibiotics as antiinflammatory agents: Roxithromycin in an unexpected role Agents Actions 1993, 38:85-90.
132. Scaglione F and Rossoni G: Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin J Antimicrob Chemother 1998, 41(SupplB):47-50.
133. Ridker PM, Shih J and Cook TJ et al.: Plasma Homocysteine Concentration, Statin Therapy, and the Risk of First Acute Coronary Events Circulation 2002, 105:1776-1779.
134. Kario K, Barton Duell P and Matsuo T et al.: High plasma homocyst(e)ine levels in elderly Japanese patients are associated with increased cardiovascular disease risk independently from markers of coagulation activation and endothelial cell damage Atherosclerosis 2001, 157:441-449.
135. Wilson PWF: Homocysteine and coronary heart disease. How great is the hazard? JAMA 2002, 288:2042-2043.
136. Omland T, Samuelsson A and Hartford M et al.: Serum Homocysteine Concentration as an Indicator of Survival in Patients With Acute Coronary Syndromes Arch Intern Med 2000, 160:1834-1840.
137. xx x: The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis JAMA 2002, 288:2015-2022.
138. Nurk E, Tell GS, Vollset SE, Nygård O, Refsum H and Ueland PM: Plasma Total Homocysteine and Hospitalizations for Cardiovascular Disease. The Hordaland Homocysteine Study Arch Intern Med 2002, 162:1374-1381.
139. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG and and the MTHFR Studies Collaboration Group: MTHFR 677CT polymorphism and risk of coronary heart disease: a meta-analysis JAMA 2002, 288:2023-2031.
140. Lentz SR, Sobey Ch G, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR and Heistad DD: Vascular Dysfunction in Monkeys with Diet-induced Hyperhomocyst(e)inemia. J. Clin Invest 1996, 98:24-29.
141. Stühlinger MC, Tsao PS and Her JS et al.: Homocysteine Impairs the Nitric Oxide Synthase Pathway Role of Asymmetric Dimethylarginine Circulation 2001, 104:25-69.
142. Key NS and McGlennen RC: Hyperhomocyst(e)inemia and thrombophilia Arch Pathol Lab Med 2002, 126:1367-1375.
143. Cavalca V, Cighetti G and Bamonti F et al.: Oxidative Stress and Homocysteine in Coronary Artery Disease Clinical Chemistry 2001, 47:887-892.
144. Durand P, Prost M, Loreau N, Lussier-Cacan S and Blache D: Impaired homocysteine metabolism and atherothrombotic disease Laboratory Investigation 2001, 81:645-672.
145. Mujumdar VS, Aru GM and Tyagi SC: Induction of oxidative stress by homocyst(e)ine impairs endothelial function, J Cellular Biochemistry 2001, 82:491-500.
146. Ungvari Z, Csiszar A, Edwards JG, Kaminski PM, Wolin MS, Kaley G and Koller A: Increased superoxide production in coronary arteries in hyperhomocysteinemia. Role of tumor necrosis factor-α, NAD(P)H oxidase, and inducible nitric oxide synthase Arterioscls Thromb Vasc Biol 2003, 23:418-424.
147. Davì G, Di Minno G and Coppola A et al.: Oxidative stress and platelet activation in homozygous homocystinuria Circulation 200, 104:1124-1128.
148. Schnyder G, Roffi M and Pin R et al.: Decreased rate of coronary restenosis after lowering of plasma homocysteine levels N Engl J Med 2001, 345:1593-1600.
149. 6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart Study: a randomized controlled trial JAMA 2002, 288:973-979.
150. Doshi SN, McDowell IFW and Moat SJ et al.: Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering Circulation 2002, 105:22-26.
151. Kranzhofer R, Browatzki M, Schmidt J and Kubler W: Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes Biochem Biophys Res Commun 1999, 257:826-828.
152. Han Y, Runge MS and Brasier AR: Angiotensin II induces interleukin-6 tanscription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors Circ Res 1999, 84:695-703.
153. Lekakis JP, Papathanassiou S and Papaioannou TG et al.: Oral Larginine improves endothelial dysfunction in patients with essential hypertension Int J Cardiol 2002, 86:317-323.
154. Pepine CJ, Schlaifer JD, Mancini GB, Pitt B, O'Neill BJ and Haber HE: Influence of smoking status on progression of endothelial dysfunction. TREND Investigators. Trial on reversing endothelial dysfunction Clin Cardiol 1998, 21:331-334.
155. Iwado Y, Yoshinaga K and Furuyama H et al.: Decreased endothelium-dependent coronary vasomotion in healthy young smokers Eur J Nucl Med Mol Imaging 2002, 8:984-990.
156. Neunteufl T, Heher S and Kostner K et al.: Contribution of nicotine to acute endothelial dysfunction in long-term smokers J Am Coll Cardiol 2002, 39:251-256.
157. Ahijevych K and Wewers ME: Passive smoking and vascular disease J Cardiovasc Nurs 2003, 18:69-74.
158. Barua RS, Ambrose JA, Eales-Reynolds LJ, DeVoe MC, Zervas JG and Saha DC: Heavy and light cigarette smokers have similar dysfunction of endothelial vasoregulatory activity: an in vivo and in vitro correlation J Am Coll Cardiol 2002, 39:1758-1763.
159. Mazzone A, Cusa C and Mazzucchelli I et al.: Cigarette smoking ad hypertension influence nitric oxide release and plasma levels of adhesion molecules Clin Chem Lab Med 2001, 39:822-826.
160. Guthikonda S, Sinkey C, Barenz T and Haynes WG: Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers Circulation 2003, 107:416-421.
161. O'Grady HL, Leahy A, McCormick PH, Fitzgerald P, Kelly CK and Bouchier-Hayes DJ: Oral folic acid improves endothelial dysfunction in cigarette smoker J Surg Res 2002, 106: 343-345.